Creative Medical Shares Soar On Positive Data from StemSpine Pilot Study
Creative Medical Technology Holdings (NASDAQ:CELZ) has announced positive two-year follow-up data from its StemSpine pilot study. The data showed significant efficacy of the StemSpine procedure for treating chronic lower back pain without any serious adverse effects reported. StemSpine is a patented procedure that utilizes a patient's bone marrow aspirate to treat chronic lower…
Benzinga ·
Benzinga
